Cargando…
The Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda
BACKGROUND: The global increase in the burden of multidrug-resistant tuberculosis (MDR-TB) underscores an urgent need for data on factors involved in generation and spread of TB drug resistance. We performed molecular analyses on a representative sample of Mycobacterium tuberculosis (MTB) isolates....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367914/ https://www.ncbi.nlm.nih.gov/pubmed/25523472 http://dx.doi.org/10.1186/s12879-014-0703-0 |
_version_ | 1782362565649629184 |
---|---|
author | Ezati, Nicholas Lukoye, Deus Wampande, Eddie M Musisi, Kenneth Kasule, George W Cobelens, Frank GJ Kateete, David P Joloba, Moses L |
author_facet | Ezati, Nicholas Lukoye, Deus Wampande, Eddie M Musisi, Kenneth Kasule, George W Cobelens, Frank GJ Kateete, David P Joloba, Moses L |
author_sort | Ezati, Nicholas |
collection | PubMed |
description | BACKGROUND: The global increase in the burden of multidrug-resistant tuberculosis (MDR-TB) underscores an urgent need for data on factors involved in generation and spread of TB drug resistance. We performed molecular analyses on a representative sample of Mycobacterium tuberculosis (MTB) isolates. Basing on findings of the molecular epidemiological study in Kampala, we hypothesized that the predominant MTB strain lineage in Uganda is negatively associated with anti-TB drug resistance and we set out to test this hypothesis. METHODS: We extracted DNA from mycobacterial isolates collected from smear-positive TB patients in the national TB drug resistance survey and carried out IS6110-PCR. To identify MTB lineages/sub lineages RT-PCR SNP was performed using specific primers and hybridization probes and the ‘melting curve’ analysis was done to distinguish the Uganda II family from other MTB families. The primary outcome was the distribution of the Uganda II family and its associations with anti-TB drug resistance and HIV infection. RESULTS: Out of the 1537 patients enrolled, MTB isolates for 1001 patients were available for SNP analysis for identification of Uganda II family, of which 973 (97%) had conclusive RT-PCR results. Of these 422 (43.4%) were of the Uganda II family, mostly distributed in the south west zone (55.0%; OR = 4.6 for comparison with other zones; 95% CI 2.83-7.57; p < 0.001) but occurred in each of the other seven geographic zones at varying levels. Compared to the Uganda II family, other genotypes as a group were more likely to be resistant to any anti-TB drug (OR(adj) =2.9; 95% CI 1.63-5.06; p = 0.001) or MDR (OR(adj) 4.9; 95% CI, 1.15-20.60; p = 0.032), even after adjusting for geographic zone, patient category, sex, residence and HIV status. It was commonest in the 25–34 year age group 159/330 (48.2%). No association was observed between Uganda II family and HIV infection. CONCLUSION: The Uganda II family is a major cause of morbidity due to TB in all NTLP zones in Uganda. It is less likely to be resistant to anti-TB drugs than other MTB strain lineages. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-014-0703-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4367914 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43679142015-03-21 The Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda Ezati, Nicholas Lukoye, Deus Wampande, Eddie M Musisi, Kenneth Kasule, George W Cobelens, Frank GJ Kateete, David P Joloba, Moses L BMC Infect Dis Research Article BACKGROUND: The global increase in the burden of multidrug-resistant tuberculosis (MDR-TB) underscores an urgent need for data on factors involved in generation and spread of TB drug resistance. We performed molecular analyses on a representative sample of Mycobacterium tuberculosis (MTB) isolates. Basing on findings of the molecular epidemiological study in Kampala, we hypothesized that the predominant MTB strain lineage in Uganda is negatively associated with anti-TB drug resistance and we set out to test this hypothesis. METHODS: We extracted DNA from mycobacterial isolates collected from smear-positive TB patients in the national TB drug resistance survey and carried out IS6110-PCR. To identify MTB lineages/sub lineages RT-PCR SNP was performed using specific primers and hybridization probes and the ‘melting curve’ analysis was done to distinguish the Uganda II family from other MTB families. The primary outcome was the distribution of the Uganda II family and its associations with anti-TB drug resistance and HIV infection. RESULTS: Out of the 1537 patients enrolled, MTB isolates for 1001 patients were available for SNP analysis for identification of Uganda II family, of which 973 (97%) had conclusive RT-PCR results. Of these 422 (43.4%) were of the Uganda II family, mostly distributed in the south west zone (55.0%; OR = 4.6 for comparison with other zones; 95% CI 2.83-7.57; p < 0.001) but occurred in each of the other seven geographic zones at varying levels. Compared to the Uganda II family, other genotypes as a group were more likely to be resistant to any anti-TB drug (OR(adj) =2.9; 95% CI 1.63-5.06; p = 0.001) or MDR (OR(adj) 4.9; 95% CI, 1.15-20.60; p = 0.032), even after adjusting for geographic zone, patient category, sex, residence and HIV status. It was commonest in the 25–34 year age group 159/330 (48.2%). No association was observed between Uganda II family and HIV infection. CONCLUSION: The Uganda II family is a major cause of morbidity due to TB in all NTLP zones in Uganda. It is less likely to be resistant to anti-TB drugs than other MTB strain lineages. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-014-0703-0) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-19 /pmc/articles/PMC4367914/ /pubmed/25523472 http://dx.doi.org/10.1186/s12879-014-0703-0 Text en © Ezati et al.; licensee BioMed Central. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Ezati, Nicholas Lukoye, Deus Wampande, Eddie M Musisi, Kenneth Kasule, George W Cobelens, Frank GJ Kateete, David P Joloba, Moses L The Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda |
title | The Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda |
title_full | The Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda |
title_fullStr | The Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda |
title_full_unstemmed | The Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda |
title_short | The Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda |
title_sort | mycobacterium tuberculosisuganda ii family and resistance to first-line anti-tuberculosis drugs in uganda |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367914/ https://www.ncbi.nlm.nih.gov/pubmed/25523472 http://dx.doi.org/10.1186/s12879-014-0703-0 |
work_keys_str_mv | AT ezatinicholas themycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda AT lukoyedeus themycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda AT wampandeeddiem themycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda AT musisikenneth themycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda AT kasulegeorgew themycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda AT cobelensfrankgj themycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda AT kateetedavidp themycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda AT jolobamosesl themycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda AT ezatinicholas mycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda AT lukoyedeus mycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda AT wampandeeddiem mycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda AT musisikenneth mycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda AT kasulegeorgew mycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda AT cobelensfrankgj mycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda AT kateetedavidp mycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda AT jolobamosesl mycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda |